<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31937582</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes.</ArticleTitle><Pagination><StartPage>350</StartPage><EndPage>358</EndPage><MedlinePgn>350-358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2019-321916</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Amyotrophic lateral sclerosis (ALS) is a complex disease with numerous pathological mechanisms resulting in a heterogeneous patient population. Using biomarkers for particular disease mechanisms may enrich a homogeneous subset of patients. In this study, we quantified chitotriosidase (Chit-1) and chitinase-3-like protein 1 (CHI3L1), markers of glial activation, in cerebrospinal fluid (CSF) and plasma and determined the cell types that express CHI3L1 in ALS.</AbstractText><AbstractText Label="METHODS">Immunoassays were used to quantify Chit-1, CHI3L1 and phosphorylated neurofilament heavy chain levels in longitudinal CSF and matching plasma samples from 118 patients with ALS, 17 disease controls (DCs), and 24 healthy controls (HCs). Immunostaining was performed to identify and quantify CHI3L1-positive cells in tissue sections from ALS, DCs and non-neurological DCs.</AbstractText><AbstractText Label="RESULTS">CSF Chit-1 exhibited increased levels in ALS as compared with DCs and HCs. CSF CHI3L1 levels were increased in ALS and DCs compared with HCs. No quantitative differences were noted in plasma for either chitinase. Patients with ALS with fast-progressing disease exhibited higher levels of CSF Chit-1 and CHI3L1 than patients with slow-progressing disease. Increased numbers of CHI3L1-positive cells were observed in postmortem ALS motor cortex as compared with controls, and these cells were identified as a subset of activated astrocytes located predominately in the white matter of the motor cortex and the spinal cord.</AbstractText><AbstractText Label="CONCLUSIONS">CSF Chit-1 and CHI3L1 are significantly increased in ALS, and CSF Chit-1 and CHI3L1 levels correlate to the rate of disease progression. CHI3L1 is expressed by a subset of activated astrocytes predominately located in white matter.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vu</LastName><ForeName>Lucas</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1869-1324</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Jiyan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovalik</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendron</LastName><ForeName>Tania</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowser</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA Robert.Bowser@dignityhealth.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071451">Chitinase-3-Like Protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.-</RegistryNumber><NameOfSubstance UI="D006596">Hexosaminidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.-</RegistryNumber><NameOfSubstance UI="C086400">chitotriosidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):338</RefSource><PMID Version="1">31937583</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071451" MajorTopicYN="N">Chitinase-3-Like Protein 1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006596" MajorTopicYN="N">Hexosaminidases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: RB is founder of Iron Horse Diagnostics, Inc, a company commercialising assays for ALS and other neurological diseases.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31937582</ArticleId><ArticleId IdType="pmc">PMC7147184</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2019-321916</ArticleId><ArticleId IdType="pii">jnnp-2019-321916</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. The Lancet 2011;377:942&#x2013;55. 10.1016/S0140-6736(10)61156-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J, An J, Bowser R, et al. . pNfH is a promising biomarker for ALS. Amyotroph Lat Scl Fr 2013;14:146&#x2013;9. 10.3109/21678421.2012.729596</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.729596</ArticleId><ArticleId IdType="pubmed">23134506</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan KB, Glass JD, Crook JE, et al. . Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84:467&#x2013;72. 10.1136/jnnp-2012-303768</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303768</ArticleId><ArticleId IdType="pubmed">23117489</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, et al. . Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:538&#x2013;48. 10.1080/21678421.2019.1646769</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. . Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 2018;84:130&#x2013;9. 10.1002/ana.25276</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Chataway T, Schultz DW, et al. . The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. PLoS One 2014;9:e87398 10.1371/journal.pone.0087398</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0087398</ArticleId><ArticleId IdType="pmc">PMC3903651</ArticleId><ArticleId IdType="pubmed">24475283</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, et al. . Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology 2017;88:1137&#x2013;43. 10.1212/WNL.0000000000003741</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, et al. . Als clinical trials review: 20 years of failure. are we any closer to Registering a new treatment? Front Aging Neurosci 2017;9:68 10.3389/fnagi.2017.00068</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Block G, Katz JS, et al. . Randomized phase 2 trial of NP001-a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm 2015;2:e100 10.1212/NXI.0000000000000100</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000100</ArticleId><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Zhang R, Block G, et al. . NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:601&#x2013;9. 10.3109/21678421.2014.951940</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.951940</ArticleId><ArticleId IdType="pmc">PMC5524125</ArticleId><ArticleId IdType="pubmed">25192333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kzhyshkowska J, Gratchev A, Goerdt S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark Insights 2007;2:117727190700200&#x2013;46. 10.1177/117727190700200023</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/117727190700200023</ArticleId><ArticleId IdType="pmc">PMC2717817</ArticleId><ArticleId IdType="pubmed">19662198</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland TE. Chitinase-Like proteins as regulators of innate immunity and tissue repair: helpful lessons for asthma? Biochem Soc Trans 2018;46:141&#x2013;51. 10.1042/BST20170108</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20170108</ArticleId><ArticleId IdType="pubmed">29351964</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Rosa M, Distefano G, Zorena K, et al. . Chitinases and immunity: ancestral molecules with new functions. Immunobiology 2016;221:399&#x2013;411. 10.1016/j.imbio.2015.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2015.11.014</ArticleId><ArticleId IdType="pubmed">26686909</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinsinger G, Gal&#xe9;otti N, Nabholz N, et al. . Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler 2015;21:1251&#x2013;61. 10.1177/1352458514561906</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458514561906</ArticleId><ArticleId IdType="pubmed">25698171</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonneh-Barkay D, Wang G, Starkey A, et al. . In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 2010;7:34 10.1186/1742-2094-7-34</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-34</ArticleId><ArticleId IdType="pmc">PMC2892443</ArticleId><ArticleId IdType="pubmed">20540736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros&#xe9;n C, Andersson C-H, Andreasson U, et al. . Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra 2014;4:297&#x2013;304. 10.1159/000362164</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000362164</ArticleId><ArticleId IdType="pmc">PMC4164083</ArticleId><ArticleId IdType="pubmed">25254036</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliardini V, Pagliardini S, Corrado L, et al. . Chitotriosidase and lysosomal enzymes as potential biomarkers of disease progression in amyotrophic lateral sclerosis: a survey clinic-based study. J Neurol Sci 2015;348:245&#x2013;50. 10.1016/j.jns.2014.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.12.016</ArticleId><ArticleId IdType="pubmed">25563799</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese A, Sharma A, Mishra P, et al. . Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin Proteomics 2013;10:19 10.1186/1559-0275-10-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1559-0275-10-19</ArticleId><ArticleId IdType="pmc">PMC4220794</ArticleId><ArticleId IdType="pubmed">24295388</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Verde F, Fang L, et al. . Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry 2018;89:239&#x2013;47. 10.1136/jnnp-2017-317138</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317138</ArticleId><ArticleId IdType="pubmed">29142138</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Th&#xe9;z&#xe9;nas M-L, et al. . Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol 2018;83:258&#x2013;68. 10.1002/ana.25143</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25143</ArticleId><ArticleId IdType="pubmed">29331073</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Bampton A, et al. . Csf chitinase proteins in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:1215&#x2013;20. 10.1136/jnnp-2019-320442</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Dedeene L, et al. . Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 2019;90:1338&#x2013;46. 10.1136/jnnp-2018-319586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanfilippo C, Longo A, Lazzara F, et al. . Chi3L1 and CHI3L2 overexpression in motor cortex and spinal cord of sALS patients. Mol Cell Neurosci 2017;85:162&#x2013;9. 10.1016/j.mcn.2017.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2017.10.001</ArticleId><ArticleId IdType="pubmed">28989002</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins MA, An J, Hood BL, et al. . Label-Free LC&#x2013;MS/MS proteomic analysis of cerebrospinal fluid identifies Protein/Pathway alterations and candidate biomarkers for amyotrophic lateral sclerosis. J Proteome Res 2015;14:4486&#x2013;501. 10.1021/acs.jproteome.5b00804</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.5b00804</ArticleId><ArticleId IdType="pmc">PMC5592736</ArticleId><ArticleId IdType="pubmed">26401960</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Williams E, Ganchev P, et al. . Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 2005;95:1461&#x2013;71. 10.1111/j.1471-4159.2005.03478.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03478.x</ArticleId><ArticleId IdType="pmc">PMC1540444</ArticleId><ArticleId IdType="pubmed">16313519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Daughrity LM, Heckman MG, et al. . Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF 72 -associated amyotrophic lateral sclerosis. Ann Neurol 2017;82:139&#x2013;46. 10.1002/ana.24980</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkar N, Kovalik T, Lorenzini I, et al. . Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis. Acta Neuropathol 2018;135:227&#x2013;47. 10.1007/s00401-017-1785-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1785-8</ArticleId><ArticleId IdType="pmc">PMC5773659</ArticleId><ArticleId IdType="pubmed">29134320</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839&#x2013;43. 10.1148/radiology.148.3.6878708</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.148.3.6878708</ArticleId><ArticleId IdType="pubmed">6878708</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-H, Petzold A, Topping J, et al. . Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry 2015;86:565&#x2013;73. 10.1136/jnnp-2014-307672</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-307672</ArticleId><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. . Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016;87:12&#x2013;20. 10.1136/jnnp-2015-311387</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311387</ArticleId><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Oeckl P, Huss A, et al. . Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 2016;79:152&#x2013;8. 10.1002/ana.24552</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24552</ArticleId><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Chen Y, Wei Q, et al. . Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis. BMC Neurol 2016;16:173 10.1186/s12883-016-0689-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-016-0689-x</ArticleId><ArticleId IdType="pmc">PMC5024522</ArticleId><ArticleId IdType="pubmed">27634542</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Steinacker P, et al. . Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry 2019;90:4&#x2013;10. 10.1136/jnnp-2018-318868</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318868</ArticleId><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Chun SJ, Boillee S, et al. . Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008;11:251&#x2013;3. 10.1038/nn2047</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2047</ArticleId><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Dom&#xed;nguez R, Colomina MJ, et al. . Ykl40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Aging 2018;10:2367&#x2013;82. 10.18632/aging.101551</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101551</ArticleId><ArticleId IdType="pmc">PMC6188478</ArticleId><ArticleId IdType="pubmed">30215603</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;rcher NR, Loggia ML, Lawson R, et al. . Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28. Neuroimage 2015;7:409&#x2013;14. 10.1016/j.nicl.2015.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2015.01.009</ArticleId><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushner PD, Stephenson DT, Wright S. Reactive astrogliosis is widespread in the subcortical white matter of amyotrophic lateral sclerosis brain. J Neuropathol Exp Neurol 1991;50:263&#x2013;77. 10.1097/00005072-199105000-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199105000-00008</ArticleId><ArticleId IdType="pubmed">2022968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgaard I, Os&#xf3;rio MJ, Kress BT, et al. . White matter astrocytes in health and disease. Neuroscience 2014;276:161&#x2013;73. 10.1016/j.neuroscience.2013.10.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2013.10.050</ArticleId><ArticleId IdType="pmc">PMC4016995</ArticleId><ArticleId IdType="pubmed">24231735</ArticleId></ArticleIdList></Reference><Reference><Citation>Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, et al. . YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer&#x2019;s disease and other tauopathies. J Neuroinflammation 2017;14:118 10.1186/s12974-017-0893-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0893-7</ArticleId><ArticleId IdType="pmc">PMC5466718</ArticleId><ArticleId IdType="pubmed">28599675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>